Business
Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker
Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration.
About this update from Aclarion, Inc.
[{"type":"text","content":" Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration. Successful commercialization of IP holds the promise of giving physicians better data to make the critical decision as to whether antibiotic therapy or surgery is the preferred treatment option. Broomfield, CO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has received a Notice of Allowance for its US Patent Application 16/224,590 titled “Magnetic Resonance Spectroscopy System and Method for Diagnosing Pain or Infection Associated with Propionic Acid”. Conventional imaging (lumbar MRI) for Chronic Low Back Pain offers important structural information but struggles to identify the actual source of pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. The patent application 16/224,590 titled “Magnetic Resonance Spectroscopy System and Method for Diagnosing Pain or Infection Associated with Propionic Acid” expands the Aclarion patent portfolio to broadly cover using MRS to identify Propionic Acid (PA), a biomarker that the literature suggests may be indicative of bacterial infection in a disc. This information may prove critical in supporting the optimal treatment of low back pain when infection is the underlying cause of pain. In these cases, effective treatment with antibiotic therapy alone may eliminate the need for surgical intervention. \"The mission of Aclarion is to give physicians better data so they can make better decisions about the care of their patients,” says Brent Ness, CEO. “We are ...